ProcartaPlex Immuno-Oncology Kits

Simultaneously measure key immune checkpoint proteins

Invitrogen Procartaplex Immuno-Oncology immunoassay kits allow simultaneous quantitation of up to 38 soluble immune checkpoint molecules for humans and numerous others for mouse, to provide a more complete profile of cancer immunity. By simultaneous measurement of key immune checkpoint proteins in a single sample, Procartaplex Immuno-Oncology immunoassays reduce the variances that could occur when testing each sample in multiple single assays. Use preconfigured panels or select from single targets to create your own custom panel to study either human or mouse immune checkpoint biomarkers.

ProcartaPlex Panel Configurator

Download our Biomarker Quantitation Assay Guide for protein and RNA

Immuno-oncology research

Recent advances in immuno-oncology (I-O) research are paving the way for innovative anti-cancer treatments that enhance or enable anti-tumor immune responses, overcome tumor evasion mechanisms, and promote conditions that favor immune protection. Two principal areas of research include the development of biotherapeutic antibodies that target immune-checkpoint pathways and the expansion of adoptive cell therapies (ACT) that rely on reintroduction of a patient’s T cells after genetic modification. Such immunotherapies may offer distinct advantages over standard cancer treatment modalities. For example, tumor-specific immune cells have the ability to migrate to areas of the body that are inaccessible by surgery and to seek out and target microscopic disease and disseminated metastases. In addition, unlike radiation and chemotherapy, the goal of immunotherapies is to act selectively against the tumor, thereby lowering the risks of damage to surrounding healthy tissue and potentially minimizing other harmful side effects.

Figure1. The cancer immunity cycle: Immune checkpoint inhibitors are targets for biotherapeutic antibodies.

T cells and natural killer (NK) cells are important players in fighting malignant cells. Soluble forms of receptors and ligands are known to exist for both T cells and NK cells. These soluble receptors and ligands can be measured with the Invitrogen Immuno- Oncology Checkpoint ProcartaPlex panels for human or mouse. Our Immuno-Oncology Checkpoint panels have been specifically designed and optimized for CCS, Serum and Plasma samples. These kits have also been validated by customers studying normal versus tumor tissues in mouse models (Figure 2).

Checkpoint panel 1 - 4 plex
Checkpoint panel 2 - 7 plex

Figure 2. Quantification of mouse immunooncology proteins. Checkpoint panel 1 (figure 2A) (4-plex) and panel 2 (figure 2B) (7 plex) were tested using homogenized MC38 or TC-1 derived tumor tissue extract from C57BI/6 mice. Tissue extracts were homogenized in RIPA buffer using a proteinase inhibitor. Some mice were non-treated and others received a treatment. The tumor tissue was removed at different time points after treatment. Differences were observed between the treated vs untreatead groups, suggesting a role for these proteins in tumor progression. Data provided by a collaborator.

Various cytokines are associated with chronic inflammation, which is cancer-promoting, or with acute inflammation, which facilitates cancer treatment. Results using ProcartaPlex Immuno-Oncology Human Checkpoint Panel 1 and Panel 2 show that the expression patterns of the soluble markers are dependent on disease state and cancer treatment (Figure 3). The systematic, simultaneous analysis of these soluble biomarkers should help to elucidate the biology of checkpoint pathways and provide a tool for monitoring response to potential therapeutic molecules.

Serum levels of checkpoint markers in melanoma samples
Figure 3. Serum levels of checkpoint markers in melanoma samples. Results as the mean of ungrouped human samples are shown for all targets of both panels.

See more applications of our ProcartaPlex assays by downloading this Immuno-Oncology whitepaper

View our human and mouse ProcartaPlex panels and Simplex products

Multiplexing protocols

Connect with us

Visit this link to answer all your questions when new to our multiplex technologies or if you need to troubleshoot unexpected results. Additionally guides and tools including videos are available for easy learning.

Email us to receive one to one consultation with a Luminex Field Application Scientist who can provide answers to determining the right products, product use and recommendations for data analysis.

Performance guarantee

If an Invitrogen immunoassay does not perform as described on our data sheet, we will replace the product at no cost to you, or if you prefer, we will provide you with a credit for future purchase.*

Learn more about performance guarantee

We're here to help

Our team of field application specialists are trained in immunoassay workflows. We can help you choose an assay or configure a panel, optimize an experiment, troubleshoot and more – face to face or on the phone at no cost.

Contact a field application specialist